Latka logo
Syncromune logo

Syncromunerevenue

Fort Lauderdale, FloridaFounded 2020

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, a potentially first-in-class platform immunotherapy designed to treat metastatic solid tumor cancers.

syncromune.comLinkedInUpdated Sep 10, 2026
Annual revenue
$5.9M
Sep 2025EST
Employees
34
Sep 2025

Syncromune revenue

Syncromune has not published its revenue. Growjo puts it at about $5.9M a year (September 2025).

$0
$2M
$4M
$0
–
$5.9M
20202021–242025
ReportedEstimateFounded 2020 at $0; every reading has its own bar
As ofRevenueSource
Sep 2025$5.9MESTGrowjo estimate

Syncromune employees

Syncromune has 34 employees (September 2025, LinkedIn).

0
10
20
30
34
2025
ReportedOne figure per year; a reported figure wins over an estimate

Syncromune FAQ

What is Syncromune's revenue?

Growjo estimates Syncromune's revenue at about $5.9M a year (September 2025). The company hasn't published its own figure.

How many employees does Syncromune have?

Syncromune has 34 employees as of September 2025, according to LinkedIn.

How this page is sourced

1 from public sources · 1 estimate. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.

Updated Sep 10, 2026Data disclaimerReport a correctionClaim this profileRun Syncromune? Join the podcast